TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06108180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: 3 treatment to eliminate active trigger points that patients have
Study: NCT05179720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: puncture stent-assisted transperineal prostate biopsy
Description: Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: puncture stent-assisted transperineal prostate biopsy
Description: Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy
Study: NCT04785339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention in adult Latinx immigrants
Description: Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
Study: NCT05227547

Intervention type: OTHER
Group type: OTHER
Intervention: Thoracic resection surgery
Description: Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
Study: NCT05197023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819 injection or placebo
Description: Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1819 injection or placebo
Description: Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
Study: NCT05116046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept
Study: NCT05659355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy (CIMT)
Description: I will apply CIMT on effected hand to observe the hand dexterity and grip strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Description: I will apply Mirror Therapy on effected hand to obeserve the hand dexterity and grip strength
Study: NCT04080791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) System
Description: The participants will undergo daily 30-minute sessions for 8 days of Virtual Reality (VR) with a VR system using commercially available default programs in addition to traditional intensive therapy regimen provided during inpatient rehab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol.
Study: NCT06140212

Intervention type: BEHAVIORAL
Intervention: Montreal Cognitive Assessment (MoCA)
Description: MoCA would be used to assess participants cognitive functioning.

Intervention type: BEHAVIORAL
Intervention: Montreal Cognitive Assessment (MoCA)
Description: MoCA would be used to assess participants cognitive functioning.

Intervention type: BEHAVIORAL
Intervention: Chinese ICOPE screening tool (self-administration and interview versions)
Description: The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.

Intervention type: BEHAVIORAL
Intervention: Chinese ICOPE screening tool (self-administration and interview versions)
Description: The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.

Intervention type: BEHAVIORAL
Intervention: Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)
Description: The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.

Intervention type: BEHAVIORAL
Intervention: Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)
Description: The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.
Study: NCT06153238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GME751
Description: 400 mg Q6W, i.v. infusion, over 24 weeks period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda - EU
Description: 400 mg Q6W, i.v. infusion, over 24 weeks period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda - US
Description: 400 mg Q6W, i.v. infusion, over 24 weeks period
Study: NCT05558176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil citrate
Description: The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.
Study: NCT06298812

Intervention type: DEVICE
Group type: OTHER
Intervention: REFLECT Scoliosis Correction System
Description: The REFLECT™ Scoliosis Correction System is designed for continued growth and mobility of the spine as well as straightening of the spine by holding the segments in a more natural anatomic position using non-rigid materials.
Study: NCT04727320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Description: Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo, once a day, one tablet at a time for 6 months
Study: NCT06171412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glu-COACH
Description: peer-mentoring support from a peer of the same cultural identity and access to a private social media group for all Black and Latinx teens

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard-of-care (ESOC)
Description: This group will receive ESOC including additional training and support on CGM beyond routine clinical practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced standard-of-care (ESOC)
Description: This group will receive ESOC including additional training and support on CGM beyond routine clinical practice.
Study: NCT05001282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELU001
Description: Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
Study: NCT04629716

Intervention type: OTHER
Intervention: Medical Cannabis
Description: Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
Study: NCT05105789

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BinaxNOW Test
Description: diagnostic test for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lollipop swab
Description: A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
Study: NCT04894123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.
Study: NCT05211739

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric contact lenses
Description: FDA-cleared silicone hydrogel toric contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric contact lenses
Description: FDA-cleared silicone hydrogel toric contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A toric contact lenses
Description: Commercially available silicone hydrogel toric contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A toric contact lenses
Description: Commercially available silicone hydrogel toric contact lenses used as indicated

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution
Study: NCT05422287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Group 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermomechanical Stimulation Device
Description: Group 2
Study: NCT06414915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250 mg, po, qd, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, iv, q3w
Study: NCT06264778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Generic name: Dabrafenib mesylate capsules Dosage form: capsule Specifications: 50mg, calculated as C23H20F3N5O2S2 Usage: Orally The dose of dabrafenib is 150 mg twice daily (equivalent to a total daily dose of 300 mg), taken at least 1 hour before or 2 hours after a meal. If you miss a dose and it is less than 6 hours before the next dose, you should not take it.~Patients who undergo fenestrated decompression will be administered the drug for 8 weeks, with curettage performed between weeks 8 and 9. Patients undergoing curettage will continue to take dabrafenib preoperatively until a few hours before surgery, but ideally, patients will take dabrafenib within 12 hours before surgery.
Study: NCT04846374

Intervention type: DEVICE
Intervention: PowerPort
Description: The study will compare pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
Study: NCT05217563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory-reframing intervention (Reframe the Pain)
Description: Parents will be taught to reminisce with their children about the vaccination experience by emphasizing positive aspects of the child's pain memory, using less utterances about pain and fear, correcting negative exaggerations in memory, and enhancing children's self-efficacy regarding their ability to cope with pain (e.g., when children used coping methods such as deep breathing, highlighting that they were brave). Parents will be instructed to reminisce with their children about the vaccine experience using the intervention strategies. Parents in the intervention groups will receive text/email reminders to use needle pain management strategies before each second vaccination appointment. Additionally, parents randomized to the intervention groups will receive text/email reminders approximately once every two weeks to use the memory-reframing principles until the second vaccination appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory-reframing intervention (Reframe the Pain)
Description: Parents will be taught to reminisce with their children about the vaccination experience by emphasizing positive aspects of the child's pain memory, using less utterances about pain and fear, correcting negative exaggerations in memory, and enhancing children's self-efficacy regarding their ability to cope with pain (e.g., when children used coping methods such as deep breathing, highlighting that they were brave). Parents will be instructed to reminisce with their children about the vaccine experience using the intervention strategies. Parents in the intervention groups will receive text/email reminders to use needle pain management strategies before each second vaccination appointment. Additionally, parents randomized to the intervention groups will receive text/email reminders approximately once every two weeks to use the memory-reframing principles until the second vaccination appointment.
Study: NCT05428254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capacitive and Resistive Radiofrequency therapy
Description: TECAR or CRRT is electromagnetic waves produced by high frequency electrical current that are able to penetrate very deep and produce a long-lasting heat which stimulates the superficial and dep tissues and produce a potent long-lasting pain-relieving effect. Mild intensity of heat produced by the long wave diathermy may be used to promote proliferation (Hernández-Bule et al., 2014) and improve the vascularization of skin and muscles.~The integration of two operational modes, Capacitive (CAP) and Resistive (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. The capacitive used an isolated metal coated electrode acts as a dielectric surface which concentrate the electrical charges near the capacitive electrode While the resistive electrode causing the diffusion of electrical charges which accumulate near bone and soft tissues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capacitive and Resistive Radiofrequency therapy
Description: TECAR or CRRT is electromagnetic waves produced by high frequency electrical current that are able to penetrate very deep and produce a long-lasting heat which stimulates the superficial and dep tissues and produce a potent long-lasting pain-relieving effect. Mild intensity of heat produced by the long wave diathermy may be used to promote proliferation (Hernández-Bule et al., 2014) and improve the vascularization of skin and muscles.~The integration of two operational modes, Capacitive (CAP) and Resistive (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. The capacitive used an isolated metal coated electrode acts as a dielectric surface which concentrate the electrical charges near the capacitive electrode While the resistive electrode causing the diffusion of electrical charges which accumulate near bone and soft tissues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.
Study: NCT05945966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral training group (UTG)
Description: stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral training group (BTG).
Description: stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
Study: NCT04877717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904
Description: SHR-A1904
Study: NCT05904054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 DNA Vaccine (ICCOV)
Description: The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 DNA Vaccine (ICCOV)
Description: The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 DNA Vaccine (ICCOV)
Description: The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 DNA Vaccine (ICCOV)
Description: The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.
Study: NCT05528250

Intervention type: OTHER
Intervention: Survey
Description: International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.

Intervention type: OTHER
Intervention: Survey
Description: International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.

Intervention type: DEVICE
Intervention: Treadmill
Description: Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.

Intervention type: DEVICE
Intervention: Treadmill
Description: Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.
Study: NCT05918172

Intervention type: DEVICE
Intervention: endotracheal cuff pressure manual measurement
Description: The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.

Intervention type: DEVICE
Intervention: endotracheal cuff pressure automatic measurement
Description: The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
Study: NCT05890872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aliya Pulsed Electric Fields (PEF)
Description: Percutaneous or Endobronchial PEF
Study: NCT05101616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab+chemotherapy
Description: camrelizumab 200mg，ivdrip，q3w； albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.